Discovery of new chromen-4-one derivatives as telomerase inhibitors through regulating expression of dyskerin

References

• Trahan C, Martel C, Dragon F. Effects of dyskeratosis congenita mutations in dyskerin, NHP2 and NOP10 on assembly of H/ACA pre-RNPs. Hum Mol Genet 2010;19:825–36.
   PubMed Web of Science ®Google Scholar
• Montanaro L. Dyskerin and cancer: more than telomerase. The defect in mRNA translation helps in explaining how a proliferative defect leads to cancer. J Pathol 2010;222:345–9.
   PubMed Web of Science ®Google Scholar
• Penzo M, Rocchi L, Brugiere S, et al. Human ribosomes from cells with reduced dyskerin levels are intrinsically altered in translation. FASEB J 2015;29:3472–82.
   PubMed Web of Science ®Google Scholar
• Martinez P, Blasco MA. Telomeric and extra-telomeric roles for telomerase and the telomere-binding proteins. Nat Rev Cancer 2011;11:161–76.
   PubMed Web of Science ®Google Scholar
• Angrisani A, Vicidomini R, Turano M, et al. Human dyskerin: beyond telomeres. Biol Chem 2014;395:593–610.
   PubMed Web of Science ®Google Scholar
• Liu B, Zhang J, Huang C, et al. Dyskerin overexpression in human hepatocellular carcinoma is associated with advanced clinical stage and poor patient prognosis. PLoS One 2012;7:e43147.
   PubMed Web of Science ®Google Scholar
• Montanaro L, Calienni M, Bertoni S, et al. Novel dyskerin-mediated mechanism of p53 inactivation through defective mRNA translation. Cancer Res 2010;70:4767–77.
   PubMed Web of Science ®Google Scholar
• Lin P, Mobasher ME, Alawi F. Acute dyskerin depletion triggers cellular senescence and renders osteosarcoma cells resistant to genotoxic stress-induced apoptosis. Biochem Bioph Res Co 2014;446:1268–75.
   PubMed Web of Science ®Google Scholar
• Gu B, Bessler M, Mason PJ. Dyskerin, telomerase and the DNA damage response. Cell Cycle 2009;8:6–10.
   PubMed Web of Science ®Google Scholar
• Rocchi L, Barbosa AJM, Onofrillo C, et al. PLoS One 2014;9:e101971.
   PubMed Web of Science ®Google Scholar
• Vanrajsinh T, Mayur P, Sumit D, et al. Exploring the anti-breast cancer potential of flavonoid analogs. RSC Adv 2016;6:79166–79.
   Web of Science ®Google Scholar
• Priyadarshani G, Amrutkar S, Nayak A, et al. Scaffold-hopping of bioactive flavonoids: Discovery of aryl-pyridopyrimidinones as potent anticancer agents that inhibit catalytic role of topoisomerase IIα. Eur J Med Chem 2016;122:43–54.
   PubMed Web of Science ®Google Scholar
• Singh S, Ahmad A, Raghuvanshi DS, et al. Synthesis of 3,5-dihydroxy-7,8-dimethoxy- 2-(4-methoxyphenyl)benzopyran-4-one derivatives as anticancer agents. Bioorg Med Chem Lett 2016;26:5322–7.
   PubMed Web of Science ®Google Scholar
• Aghdassi A, Phillips P, Dudeja V, et al. Experimental therapeutics, molecular targets, and chemical biology. Cancer Res 2007;67:616–25.
   PubMed Web of Science ®Google Scholar
• Mouria M, Gukovskaya AS, Jung Y, et al. Food-derived polyphenols inhibit pancreatic cancer growth through mitochondrial cytochrome c release and apoptosis. Int J Cancer 2002;98:761–9.
   PubMed Web of Science ®Google Scholar
• Shih YW, Wu PF, Lee YC, et al. Myricetin suppresses invasion and migration of human lung adenocarcinoma A549 cells: possible mediation by blocking the ERK signaling pathway. J Agric Food Chem 2009;57:3490–9.
   PubMed Web of Science ®Google Scholar
• Walker EH, Pacold ME, Perisic O, et al. Structural determinants of phosphoinositide 3-kinase inhibition by wortmannin, LY294002, quercetin, myricetin, and staurosporine. Mol Cell 2000;6:909–19.
   PubMed Web of Science ®Google Scholar
• Agullo G, Gamet-Payrastre L, Manenti S, et al. Relationship between flavonoid structure and inhibition of phosphatidylinositol 3-kinase: a comparison with tyrosine kinase and protein kinase C inhibition. Biochem Pharmacol 1997;53:1649–57.
   PubMed Web of Science ®Google Scholar
• Hou DX, Kai K, Li JJ, et al. Anthocyanidins inhibit activator protein 1 activity and cell transformation: structure-activity relationship and molecular mechanisms. Carcinogenesis 2004;25:29–36.
   PubMed Web of Science ®Google Scholar
• Williams RJ, Spencer JP, Rice-Evans C. Absorption and metabolism of flavonoids. Free Radic Biol Med 2004;36:838–49.
   PubMed Web of Science ®Google Scholar
• Koren J, Jinwal UK, Jin Y, et al. J. Facilitating Akt clearance via manipulation of Hsp70 activity and levels. Biol Chem 2010;285:2498–505.
   Web of Science ®Google Scholar
• Ying XZ, Chen XW, Feng YZ, et al. Myricetin enhances osteogenic differentiation through the activation of canonical Wnt/β-catenin signaling in human bone marrow stromal cells. Eur J Pharmacol 2014;738:22–30.
   PubMed Web of Science ®Google Scholar
• Soma M, Jagannath J, Pallabi S, et al. Myricetin arrests human telomeric G-quadruplex structure: a new mechanistic approach as an anticancer agent. Mol BioSyst 2016;12:2506–18.
   PubMed Web of Science ®Google Scholar
• Amin KM, Abou-Seri SM, Awadallah FM, et al. Synthesis and anticancer activity of some 8-substituted-7-methoxy-2H-chromen-2-one derivatives toward hepatocellular carcinoma HepG2 cells. Eur J Med Chem 2015;90:221–31.
   PubMed Web of Science ®Google Scholar
• Bhattacharya S, Chaudhuri P, Jain AK, et al. Symmetrical bisbenzimidazoles with benzenediyl spacer: the role of the shape of the ligand on the stabilization and structural alterations in telomeric G-quadruplex DNA and telomerase inhibition. Bioconjug Chem 2010;21:1148–59.
   PubMed Web of Science ®Google Scholar
• Prasad R, Kumar S, Bhattacharya S. Synthesis and biological evaluation of novel 4,5-dihydropyrazole derivatives as potent anticancer and antimicrobial agents. Med Chem. Res 2013;22:2061–78.
   Web of Science ®Google Scholar
• Xue W, Song BA, Zhao HJ, et al. Novel myricetin derivatives: design、synthesis and anticancer activity. Eur J Med Chem 2015;97:155–63.
   PubMed Web of Science ®Google Scholar
• Liu XH, Li J, Shi JB, et al. Design and synthesis of novel 5-phenyl-N-piperidine ethanone containing 4,5-dihydropyrazole derivatives as potential antitumor agents. Eur J Med Chem 2012;51:294–9.
   PubMed Web of Science ®Google Scholar
• Fatemi A, Safa M. MST-312 induces G2/M cell cycle arrest and apoptosis in APL cells through inhibition of telomerase activity and suppression of NF-κB pathway. Tumour Biol 2015;36:8425–37.
   PubMedGoogle Scholar
• Vulliamy T, Beswick R, Kirwan M, et al. Mutations in the telomerase component NHP2 cause the premature ageing syndrome dyskeratosis congenita. PNAS 2008;105:8073–8.
   PubMed Web of Science ®Google Scholar
• Walne AJ, Vulliamy T, Marrone A, et al. Genetic heterogeneity in autosomal recessive dyskeratosis congenita with one subtype due to mutations in the telomerase-associated protein NOP10. Hum Mol Genet 2007;16:1619–29.
   PubMed Web of Science ®Google Scholar
• Vasuri F, Rocchi L, Degiovanni A, et al. Dyskerin expression in human fetal, adult and neoplastic intrahepatic bile ducts: correlations with cholangiocarcinoma aggressiveness. Histopathology 2015;66:244–51.
   PubMed Web of Science ®Google Scholar
• Bellodi C, Krasnykh O, Haynes N, et al. Loss of function of the tumor suppressor DKC1 perturbs p27 translation control and contributes to pituitary tumorigenesis. Cancer Res 2010;70:6026–35.
   PubMed Web of Science ®Google Scholar
• Sekaran V, Soares J, Jarstfer MB. Telomere maintenance as a target for drug discovery. J Med Chem 2014;57:521–38.
   PubMed Web of Science ®Google Scholar